| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,030,000 |
| Market
Cap: |
18.45(B) |
| Last
Volume: |
735,773 |
Avg
Vol: |
726,924 |
| 52
Week Range: |
$143.71 - $212.05 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 824 |
| Guru Rank Value : 0.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
46,855 |
76,855 |
102,504 |
247,093 |
| Total Sell Value |
$7,107,715 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
| Total People Sold |
6 |
7 |
8 |
9 |
| Total Sell Transactions |
11 |
12 |
18 |
35 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Paul Steven M |
Director |
– • – |
2020-12-18 |
4 |
OE |
$9.30 |
$139,500 |
D/D |
15,000 |
16,000 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2020-12-07 |
4 |
GA |
$0.00 |
$0 |
I/I |
235,633 |
266,899 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2020-12-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
235,633 |
0 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2020-11-25 |
4 |
AS |
$124.30 |
$3,746,749 |
D/D |
(30,000) |
235,633 |
|
14% |
|
| Sharp Philip A |
Director |
– • – |
2020-11-25 |
4 |
OE |
$9.30 |
$279,000 |
D/D |
30,000 |
265,633 |
|
- |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-11-19 |
4 |
AS |
$123.55 |
$4,319,025 |
D/D |
(34,765) |
197,589 |
|
15% |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-11-19 |
4 |
OE |
$9.14 |
$317,752 |
D/D |
34,765 |
232,354 |
|
- |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-09-29 |
4 |
AS |
$140.00 |
$135,940 |
D/D |
(971) |
14,119 |
|
13% |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2020-09-29 |
4 |
OE |
$42.22 |
$40,996 |
D/D |
971 |
15,090 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-09-09 |
4 |
AS |
$122.66 |
$5,487,594 |
D/D |
(44,530) |
70,343 |
|
36% |
|
| Greene Barry E |
President |
• – – |
2020-09-09 |
4 |
OE |
$9.14 |
$407,004 |
D/D |
44,530 |
114,873 |
|
- |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-08-20 |
4 |
AS |
$135.09 |
$4,732,542 |
D/D |
(34,765) |
197,589 |
|
-6% |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2020-08-20 |
4 |
OE |
$9.14 |
$317,752 |
D/D |
34,765 |
232,354 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-08-10 |
4 |
OE |
$42.22 |
$349,871 |
D/D |
4,931 |
67,167 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-07-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,486 |
0 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-07-16 |
4 |
GA |
$0.00 |
$0 |
I/I |
155 |
155 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-07-16 |
4 |
GA |
$0.00 |
$0 |
D/D |
3,176 |
65,412 |
|
- |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-07-13 |
4 |
AS |
$157.16 |
$7,591,790 |
D/D |
(47,250) |
2,992 |
|
-18% |
|
| Keating Laurie |
EVP, Chief Legal Officer |
• – – |
2020-07-13 |
4 |
OE |
$42.22 |
$3,116,066 |
D/D |
35,750 |
50,242 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-07-10 |
4 |
AS |
$161.00 |
$7,508,879 |
D/D |
(46,639) |
4,820 |
|
-24% |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-07-10 |
4 |
OE |
$77.10 |
$3,595,867 |
D/D |
46,639 |
51,459 |
|
- |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-07-09 |
4 |
AS |
$161.00 |
$1,808,996 |
D/D |
(11,236) |
4,820 |
|
-21% |
|
| Greenstreet Yvonne |
Chief Operating Officer |
• – – |
2020-07-09 |
4 |
OE |
$42.22 |
$484,743 |
D/D |
11,236 |
16,056 |
|
- |
|
| Greene Barry E |
President |
• – – |
2020-07-07 |
4 |
AS |
$159.99 |
$3,562,177 |
D/D |
(22,265) |
62,236 |
|
-18% |
|
| Greene Barry E |
President |
• – – |
2020-07-07 |
4 |
OE |
$9.14 |
$203,502 |
D/D |
22,265 |
84,501 |
|
- |
|
475 Records found
|
|
Page 7 of 19 |
|
|
6.01 (4.18%) 
